Skip to content

Study · Randomized controlled trial · 2024

16 results

Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.

Mather KJ, Mari A, Heise T, DeVries JH, Hua M, Urva S, Coskun T, Haupt A, Heine RJ, Pratt E, Thomas MK, Milicevic Z

The Journal of clinical endocrinology and metabolism1 Nov 2024Cited by 24 (Europe PMC)

PMID38795393 (opens in a new tab)DOI10.1210/clinem/dgae319 (opens in a new tab)PepBankPUB-38795393
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, tirzepatide reduced fasting glucose significantly more than semaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered fasting blood glucose more than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting glucose
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide significantly reduced fasting glucose and MMTT total glucose area under the curve (AUC) vs semaglutide (P < .01)
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, tirzepatide reduced total glucose AUC in the mixed-meal test significantly more than semaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered total blood glucose after a test meal more than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal glucose AUC during meal test
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide significantly reduced fasting glucose and MMTT total glucose area under the curve (AUC) vs semaglutide (P < .01).
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, incremental glucose AUC did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn adults with type 2 diabetes, the rise in blood glucose after a test meal did not differ significantly between tirzepatide and semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeIncremental glucose AUC during meal test
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Incremental glucose AUC did not differ significantly between treatments
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, incremental glucose AUC did not differ significantly between semaglutide and tirzepatide.

    In plain wordsIn adults with type 2 diabetes, the rise in blood glucose after a test meal did not differ significantly between semaglutide and tirzepatide.

    Peptide
    Semaglutide
    Outcome
    No significant changeIncremental glucose AUC during meal test
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Incremental glucose AUC did not differ significantly between treatments
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, tirzepatide reduced total insulin secretion rate AUC significantly more than semaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered the total insulin output after a test meal more than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal insulin secretion rate AUC
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    A greater reduction in total ISR AUC was achieved with tirzepatide vs semaglutide (P < .01)
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, tirzepatide improved insulin sensitivity significantly more than semaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide improved insulin sensitivity more than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseInsulin sensitivity
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    in the context of greater improvement in insulin sensitivity with tirzepatide (P < .01).
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, ISR7.2 increased significantly more with tirzepatide than with semaglutide, showing improved beta-cell glucose sensitivity.

    In plain wordsIn adults with type 2 diabetes, tirzepatide improved beta-cell sensitivity to glucose more than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseInsulin secretion rate at 7.2 mmol/L glucose (ISR7.2)
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    ISR7.2 was significantly increased with tirzepatide vs semaglutide (P < .05), showing improved β-CGS.
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, meal-test beta-cell glucose sensitivity increased but did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn adults with type 2 diabetes, beta-cell sensitivity to glucose rose but did not differ significantly between tirzepatide and semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMMTT-derived beta-cell glucose sensitivity
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    MMTT-derived β-CGS was increased but not significantly different between treatments.
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, meal-test beta-cell glucose sensitivity increased but did not differ significantly between semaglutide and tirzepatide.

    In plain wordsIn adults with type 2 diabetes, beta-cell sensitivity to glucose rose but did not differ significantly between semaglutide and tirzepatide.

    Peptide
    Semaglutide
    Outcome
    No significant changeMMTT-derived beta-cell glucose sensitivity
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    MMTT-derived β-CGS was increased but not significantly different between treatments.
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, tirzepatide reduced fasting glucagon.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered fasting glucagon.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting glucagon
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Both treatments reduced fasting glucagon and total glucagon AUC
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, tirzepatide reduced total glucagon AUC in the meal test.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered glucagon levels after a test meal.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal glucagon AUC
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Both treatments reduced fasting glucagon and total glucagon AUC
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, semaglutide reduced fasting glucagon.

    In plain wordsIn adults with type 2 diabetes, semaglutide lowered fasting glucagon.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting glucagon
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Both treatments reduced fasting glucagon and total glucagon AUC
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, semaglutide reduced total glucagon AUC in the meal test.

    In plain wordsIn adults with type 2 diabetes, semaglutide lowered glucagon levels after a test meal.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal glucagon AUC
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Both treatments reduced fasting glucagon and total glucagon AUC
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, glucagon AUC was reduced significantly more with tirzepatide than with semaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered glucagon after a test meal more than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal glucagon AUC versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    with glucagon AUC significantly reduced with tirzepatide vs semaglutide (P < .01).
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  15. 15HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, the estimated hepatic insulin-to-glucagon ratio did not change substantially with tirzepatide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide did not substantially change the estimated liver insulin-to-glucagon ratio.

    Peptide
    Tirzepatide
    Outcome
    No significant changeEstimated hepatic insulin-to-glucagon ratio
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Liver
    Studied dose
    15 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    The estimated hepatic insulin-to-glucagon ratio did not change substantially with either treatment.
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.
  16. 16HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, the estimated hepatic insulin-to-glucagon ratio did not change substantially with semaglutide.

    In plain wordsIn adults with type 2 diabetes, semaglutide did not substantially change the estimated liver insulin-to-glucagon ratio.

    Peptide
    Semaglutide
    Outcome
    No significant changeEstimated hepatic insulin-to-glucagon ratio
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Liver
    Studied dose
    1 mg · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    The estimated hepatic insulin-to-glucagon ratio did not change substantially with either treatment.
    2 context sentences
    Summary · context
    A 28-week double-blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany.
    Summary · context
    Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.